stockrowXencor, Inc.
XNCR Healthcare Biotechnology
Xencor, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $125.6 million, up 13.7% from fiscal 2024.
- Revenue
- +17.5%
- EPS
- +29.3%
- Free cash flow
- −52.9%
Quarter to June 2026, against a year earlier
Follow XNCR
Alert me
Xencor, Inc. (XNCR) Current ratio
Xencor, Inc.'s current ratio at the end of the quarter to 30 June 2026 was 6.4×, up 0.1× from fiscal 2025 (6.3×). Over the past ten years it has ranged from 1.3× (fiscal 2016) to 10.6× (fiscal 2022); the current reading is higher than 64% of that period. That is above the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 6.3× | (5.33%) |
| FY2024 | 6.6× | (23.17%) |
| FY2023 | 8.6× | (18.71%) |
| FY2022 | 10.6× | 76.32% |
| FY2021 | 6.0× | 13.89% |
| FY2020 | 5.3× | (37.22%) |
| FY2019 | 8.4× | 43.10% |
| FY2018 | 5.9× | 84.48% |
| FY2017 | 3.2× | 138.45% |
| FY2016 | 1.3× | (40.74%) |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 6.4× | (2.77%) |
| Mar 2026 | 6.6× | 5.10% |
| Dec 2025 | 6.3× | 4.33% |
| Sep 2025 | 6.0× | 12.24% |
| 42 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| MBX MBX Biosciences, Inc. compare | 18.1× |
| BEAM Beam Therapeutics Inc. compare | 13.0× |
| PHVS Pharvaris N.V. compare | 11.9× |
| NAMS NewAmsterdam Pharma Company N.V. compare | 11.8× |
| XNCR Xencor, Inc. | 6.4× |
| ADMA ADMA Biologics Inc compare | 6.0× |
| RXRX Recursion Pharmaceuticals, Inc. compare | 5.0× |
| RCUS Arcus Biosciences, Inc. compare | 3.3× |
| ZLAB Zai Lab Limited Unsponsored ADR compare | 2.0× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on XNCR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement